Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Lecithin/chitosan nanoparticles for transdermal delivery of melatonin (CROSBI ID 179549)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Hafner, Anita ; Lovrić, Jasmina ; Pepić, Ivan ; Filipović-Grčić, Jelena Lecithin/chitosan nanoparticles for transdermal delivery of melatonin // Journal of microencapsulation, 28 (2011), 8; 807-815. doi: 10.3109/02652048.2011.622053

Podaci o odgovornosti

Hafner, Anita ; Lovrić, Jasmina ; Pepić, Ivan ; Filipović-Grčić, Jelena

engleski

Lecithin/chitosan nanoparticles for transdermal delivery of melatonin

In this study, the potential of lecithin/chitosan nanoparticles (NPs) as colloidal nanosystem for transdermal melatonin delivery was investigated. Mean diameter and zeta-potential of NPs differing in lecithin type (Lipoid S45 and S100) and chitosan content ranged between 113.7 and 331.5 nm and 4.6 and 31.2 mV, respectively. Melatonin loadings were up to 7.2%. The potential of lecithin/chitosan NPs to enhance transdermal melatonin delivery was investigated by determining the drug flux across dermatomed porcine skin and its skin deposition. Lecithin/chitosan NPs provided 1.3–2.3-fold higher flux compared to melatonin solution. The highest flux, 9.0 ± 0.21 µg/cm2/h, was observed for S45 lecithin/chitosan NPs with lecithin/chitosan weight ratio of 20:1. NP possible cytotoxicity in vitro was evaluated using human skin keratinocytes and fibroblasts. It was demonstrated that lecithin/chitosan NPs can be applied to skin cells at concentrations up to 200 µg/mL without inducing plasma membrane damage or cell viability decrease.

melatonin; lecithin; chitosan; nanoparticles; transdermal permeability

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

28 (8)

2011.

807-815

objavljeno

0265-2048

10.3109/02652048.2011.622053

Povezanost rada

Farmacija

Poveznice
Indeksiranost